Menu
05/11/2019
QUB Partakes In New Cystic Fibrosis Trial
Researchers at Queen's University Belfast have been involved in ground-breaking research that holds promise for a vast majority of those with cystic fibrosis.
The researchers identified how a combination of three drugs known as 'triple therapy' can successfully treat the majority of people living with CF by tackling the underlying cause of the disease.
The research comes in the wake of confirmation that life-saving drugs Orkambi and Symkevi are to be made available to local patients.
The new trial involves a drug that targets the root cause of cystic fibrosis, a genetic condition which clogs up the lungs and digestive system, making breathing difficult resulting in an early death for those affected.
Cystic fibrosis is a genetic condition affecting more than 10,400 people in the UK. It is a progressive and life-threatening disease which results in the formation of thick mucus that builds up in the lungs and other parts of the body. It leads to severe respiratory infections that damage the lungs and cause them to fail.
CF is caused by a defective protein that results from mutations in the CFTR gene. The most common mutation is the F508del mutation. Although there is currently no cure for CF, it is possible to help control the symptoms and delay complications to make the condition easier to live with.
Dr Damian Downey is a Clinical Senior Lecturer at the Wellcome-Wolfson Institute for Experimental Medicine co-author on the worldwide trial to assess the safety and efficacy of a new triple drug combination (TRIKAFTATM) in patients with CF aged 12 years and older. The study involved a four-week, randomized, double-blind, active-controlled trial in 107 patients who had two copies of the F508del mutation.
Dr Downey explained: "The trial was a success in demonstrating that this drug combination can potentially treat up to 90% of people with CF by addressing the underlying cause of their disease. This new 'triple therapy' has the potential to transform the lives of people with CF. It results in a significant improvement in lung function and quality of life and also reduces the frequency of chest infections. This treatment will likely alter the future of CF care."
The study was conducted with funding from Vertex Pharmaceuticals, which developed the triple-combination drug therapy, known as Trikafta. Last week, the Food and Drug Administration approved Trikafta for use with about 90 percent of patients with cystic fibrosis — those who have the most common cystic fibrosis gene mutation and are 12 or older.
(JG/CM)
The researchers identified how a combination of three drugs known as 'triple therapy' can successfully treat the majority of people living with CF by tackling the underlying cause of the disease.
The research comes in the wake of confirmation that life-saving drugs Orkambi and Symkevi are to be made available to local patients.
The new trial involves a drug that targets the root cause of cystic fibrosis, a genetic condition which clogs up the lungs and digestive system, making breathing difficult resulting in an early death for those affected.
Cystic fibrosis is a genetic condition affecting more than 10,400 people in the UK. It is a progressive and life-threatening disease which results in the formation of thick mucus that builds up in the lungs and other parts of the body. It leads to severe respiratory infections that damage the lungs and cause them to fail.
CF is caused by a defective protein that results from mutations in the CFTR gene. The most common mutation is the F508del mutation. Although there is currently no cure for CF, it is possible to help control the symptoms and delay complications to make the condition easier to live with.
Dr Damian Downey is a Clinical Senior Lecturer at the Wellcome-Wolfson Institute for Experimental Medicine co-author on the worldwide trial to assess the safety and efficacy of a new triple drug combination (TRIKAFTATM) in patients with CF aged 12 years and older. The study involved a four-week, randomized, double-blind, active-controlled trial in 107 patients who had two copies of the F508del mutation.
Dr Downey explained: "The trial was a success in demonstrating that this drug combination can potentially treat up to 90% of people with CF by addressing the underlying cause of their disease. This new 'triple therapy' has the potential to transform the lives of people with CF. It results in a significant improvement in lung function and quality of life and also reduces the frequency of chest infections. This treatment will likely alter the future of CF care."
The study was conducted with funding from Vertex Pharmaceuticals, which developed the triple-combination drug therapy, known as Trikafta. Last week, the Food and Drug Administration approved Trikafta for use with about 90 percent of patients with cystic fibrosis — those who have the most common cystic fibrosis gene mutation and are 12 or older.
(JG/CM)
Related Northern Ireland News Stories
Click here for the latest headlines.
20 November 2024
Hard-Hitting Road Safety Message Delivered To Young People
Over 800 young people from schools in Lisburn and Castlereagh attended a hard-hitting road safety message at the PSNI Road Safe Roadshow on 19 November. The roadshow, supported by AXA Insurance and the Northern Ireland Road Safety Partnership, aims to educate young drivers about the dangers of irresponsible driving.
Hard-Hitting Road Safety Message Delivered To Young People
Over 800 young people from schools in Lisburn and Castlereagh attended a hard-hitting road safety message at the PSNI Road Safe Roadshow on 19 November. The roadshow, supported by AXA Insurance and the Northern Ireland Road Safety Partnership, aims to educate young drivers about the dangers of irresponsible driving.
15 November 2024
New Pathway To Support Young People With Diabetes
Health Minister Mike Nesbitt has welcomed the launch of a new Regional Young Adults' Progression Pathway designed to support young people with Type 1 diabetes as they transition to adult services.
New Pathway To Support Young People With Diabetes
Health Minister Mike Nesbitt has welcomed the launch of a new Regional Young Adults' Progression Pathway designed to support young people with Type 1 diabetes as they transition to adult services.
26 January 2005
Funding secured for cystic fibrosis researchers
Cystic fibrosis researchers from Queen's University have won a share of a major £500,000 funding grant. The Cystic Fibrosis Trust was awarded £509,759 from the Big Lottery Fund to help improve the lives of disadvantaged children and young adults with the disease.
Funding secured for cystic fibrosis researchers
Cystic fibrosis researchers from Queen's University have won a share of a major £500,000 funding grant. The Cystic Fibrosis Trust was awarded £509,759 from the Big Lottery Fund to help improve the lives of disadvantaged children and young adults with the disease.
14 August 2024
Grand Central Construction Team To Raise Funds For Cystic Fibrosis Trust
Ten members of the construction team delivering Belfast Grand Central Station are to participate in a 48-hour cycling challenge to raise funds on behalf of Cystic Fibrosis Trust. The group of amateur cyclists from joint venture Farrans Sacyr, will set out from Glasgow on 21 September and aim to reach Fort William, 104 miles away, in just 48 hous.
Grand Central Construction Team To Raise Funds For Cystic Fibrosis Trust
Ten members of the construction team delivering Belfast Grand Central Station are to participate in a 48-hour cycling challenge to raise funds on behalf of Cystic Fibrosis Trust. The group of amateur cyclists from joint venture Farrans Sacyr, will set out from Glasgow on 21 September and aim to reach Fort William, 104 miles away, in just 48 hous.
13 November 2019
CF Drugs To Be Available Within Weeks
Clinicians will begin prescribing life-changing drugs to local Cystic Fibrosis patients in a matter of weeks, the Department of Health has confirmed. Orkambi, Symkevi and Kalydeco will be made available through a deal with manufacturer Vertex Pharmaceuticals which follows similar arrangements in England and Scotland.
CF Drugs To Be Available Within Weeks
Clinicians will begin prescribing life-changing drugs to local Cystic Fibrosis patients in a matter of weeks, the Department of Health has confirmed. Orkambi, Symkevi and Kalydeco will be made available through a deal with manufacturer Vertex Pharmaceuticals which follows similar arrangements in England and Scotland.
-
Northern Ireland WeatherToday:A showery start with outbreaks most frequent north of Lough Neagh and through the morning, before dwindling during the afternoon as the northwest breezes ease and brighter spells of weak sunshine prosper. Maximum temperature 8 °C.Tonight:A dry night, save for a few light showers around the coasts, with prolonged clear spells and light winds bringing a frosty dawn for many in central and southern parts. Minimum temperature -3 °C.
